PA
ARIA

Pinnacle Associates’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Pinnacle Associates’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-29,680
Closed -$369K – 676
2016
Q4 		$369K Sell
29,680
-4,550
-13% -$54.8K 0.01% 522
2016
Q3 		$469K Buy
34,230
+460
+1% +$4.62K 0.01% 481
2016
Q2 		$250K Sell
33,770
-7,000
-17% -$52.5K 0.01% 565
2016
Q1 		$261K Sell
40,770
-6,950
-15% -$39K 0.01% 547
2015
Q4 		$298K Sell
47,720
-8,800
-16% -$57.8K 0.01% 538
2015
Q3 		$330K Buy
56,520
+5,000
+10% +$38.5K 0.01% 509
2015
Q2 		$426K Sell
51,520
-2,300
-4% -$20.3K 0.01% 488
2015
Q1 		$443K Sell
53,820
-2,100
-4% -$15.5K 0.01% 477
2014
Q4 		$384K Sell
55,920
-6,200
-10% -$38.8K 0.01% 490
2014
Q3 		$335K Sell
62,120
-770
-1% -$4.5K 0.01% 511
2014
Q2 		$401K Buy
62,890
+8,870
+16% +$61K 0.01% 486
2014
Q1 		$435K Buy
+54,020
New +$421K 0.01% 469
2013
Q3 		– Sell
-12,250
Closed -$214K – 581
2013
Q2 		$214K Buy
+12,250
New +$217K ﹤0.01% 517

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Pinnacle Associates's ARIA Position: Q1 2017 in Review

Pinnacle Associates sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 29,680 shares — an estimated $369K sold.

Pinnacle Associates first reported a position in ARIA in Q2 2013 and held it in 13 quarters. The position peaked at $469K in Q3 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Pinnacle Associates reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Pinnacle Associates sold 29,680 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $369K.
  • Pinnacle Associates first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
  • Pinnacle Associates's Ariad Pharmaceuticals Inc position peaked at $469K in Q3 2016.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Pinnacle Associates's 13F filing for Q1 2017, filed 10 May 2017.